Shares of German biotechnology company BioNTech SE (BNTX) are down 4 percent on Tuesday's trading despite the company announcing that it would likely generate up to 17 billion euros or $19 billion in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer Inc. (PFE).

Create Account

Dark

chart

exchange

RTTNews | Jan 11, 2022 10:21AM EST

10:20 Tuesday, January 11, 2022 (RTTNews.com) - Shares of German biotechnology company BioNTech SE (BNTX) are down 4 percent on Tuesday's trading despite the company announcing that it would likely generate up to 17 billion euros or $19 billion in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer Inc. (PFE).

The company expects 13-17 billion euros revenues from the vaccine this year, which compares to the outlook for 16-17 billion euros for 2021.

Currently, at $220.37, the stock has traded between $90.29 and $464.00 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3254315/biontech-shares-fall-4-despite-positive-outlook-for-2022-vaccine-revenues.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved